Rhythm Wins Reimbursement For Obesity Drug Imcivree In France & England

France is set to become the first country in Europe to fund Imcivree for a second – and as yet unapproved – indication. Meanwhile, England has agreed to reimburse the drug for its approved indication as did Germany earlier this year. Reimbursement discussions are underway in the rest of Europe.

More patients in Europe will get access to Imcivree for obesity • Source: Alamy

Imcivree (setmelanotide), Rhythm Pharmaceuticals’ first-of-a-kind treatment for patients with rare genetic disorders of obesity and insatiable hunger, has won early access funding approval in France for a second indication that is expected to receive EU marketing authorization soon. In addition, the melanocortin-4 receptor (MC4R) agonist been recommended for reimbursement in England for the first time.

The French authorities agreed to fund Imcivree under their early access authorization scheme (autorisation d’accès précoce) for the treatment of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet